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Abstract 
Introduction: Plasmodium vivax malaria affects billions of people annually. This study aimed to note the presentations and complications and 
subsequently to identify the determinants of in-patient hospital care of P. vivax malaria patients presenting to a tertiary care hospital in 
Karachi, Pakistan. Severity of the shock was also assessed using a shock index. 
Methodology: This study descriptive cross-sectional study was conducted at the Emergency Department of Aga Khan University Hospital, 
Karachi. All adult patients with a positive P. vivax peripheral film and/or immunochromatography admitted through the department were 
studied during 2009. Data was entered and analyzed using SPSS version 16. Keeping the length of stay at a cut-off of 48 hours after 
admission, the independent Student-t test was applied. Level of significance was taken at 0.05. 
Results: A total of 97 patients were included in the study. Fever was the most common presentation. A significant number of patients had 
nonspecific complaints, but tachycardia, altered mental status, and adult respiratory distress syndrome were important findings. Mean shock 
index was 1 (SD 0.26). Common reasons for admission were thrombocytopenia and dehydration. Some patients were admitted for more than 
48 hours. Complications included pneumonia and bleeding requiring platelet transfusion. 
Conclusion: This study highlights that the debilitating impact of P. vivax malaria remains high. Although the effects of severe vivax malaria 
can be contained through aggressive resuscitation and specific therapy, sensitivity and awareness of this complicated course must be 
highlighted among caregivers. 
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Introduction 
Plasmodium vivax (P. vivax) malaria is a public 
health problem that puts billions of the world’s 
population at risk of infection as highlighted in the 
World Malaria Report 2010 [1]. Despite malaria 
control strategies, an estimated 100-300 million cases 
are reported each year [2, 3]. P. vivax has a greater 
ability to survive in non-conducive environments; 
however, it is still considered to run a relatively 
benign disease course as compared to Plasmodium 
falciparum. This impression has not only resulted in a 
lesser focus on control strategies, funding and 
research, but its economic burden on health-care 
systems has also been underestimated [4-6]. 
Outside Africa, more than 50% of malaria cases 
are caused by P. vivax. Most of the disease burden is 
born by countries in the Middle East, South Asia, 
Western Pacific and Latin America [3]. Pakistan has 
also contributed to this burden with drug resistant P. 
falciparum and P. vivax malaria [7]. In Pakistan, 
malaria has been a persistent problem despite the 
Malaria Eradication Program of the 1970s. A recent 
study from Pakistan revealed that anti-folate 
resistance mutations were detected in 93.5% of P. 
vivax isolates [8]. 
P. vivax malaria is commonly called “benign 
tertian malaria”; however, features of acute 
presentation are confounded by multiple relapses 
occurring as a result of the activation of dormant 
hypnozoites residing in the liver. The classical 
clinical presentation in a non-immune patient causes 
high-grade fever with headaches and prostration with 
a regular 48-hour periodicity. Most patients are 
treated as outpatients in endemic areas, with 
chloroquine being the cornerstone of treatment [7-9]. 
Recently, changes have been noted in the 
epidemiology, resistance patterns and clinical 
presentations of P. vivax. A variety of common 
gastrointestinal symptoms have been noted [3-4,10-
11], in addition to  severe anaemia, pulmonary 
complications, and renal failure reported from 
various parts of the world [12-14]. 
 The rapid progression of a febrile illness into a 
systemic infection requires advanced care with the 
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need of aggressive resuscitation and in-hospital care. 
Frequent observations of such complicated P. vivax 
patients presenting to our Emergency Department 
(ED) led us to conduct this study to note the 
presentations and complications and subsequently to 
identify the determinants of in-patient hospital care of 
P. vivax malaria patients presenting to a tertiary care 
hospital in Karachi, Pakistan. Clinical severity of the 
disease was assessed using the Shock Index (SI) 
which reflects the hemodynamic response to the 
shock [15,16]. 
 
Methodology 
This descriptive cross-sectional study was 
conducted in the ED of Aga Khan University 
Hospital, Karachi. Being one of the busier tertiary 
care facilities and a major referral centre of the city, 
our department has an annual patient turnover of 
50,000 with a 38% admission rate. 
All adult patients with a positive P. vivax 
peripheral film and/or immunochromatography (MP-
ICT) admitted through the ED were enrolled. The 
medical records were extracted for all P. vivax 
International Classification of Diseases-9 coded 
patients from January 2009 to December 2009. 
Patients who were managed as outpatients were not 
included in the study. 
A pre-tested data collection tool was designed 
with variables including the patients’ demographic 
details as well as clinical presentation. Presenting 
complaints, co-morbidities, hemodynamic parameters 
at arrival, and physical examination findings were 
noted. Laboratory workup including haemoglobin 
(Hb), haematocrit (Hct), platelets (Plt) count, total 
leukocyte count (TLC), and serum creatinine (SCr) 
were checked for malarial parasites (MP) and MP 
ICT was also recorded. Further in-patient 
management, follow-up laboratory tests, inpatient 
complications, length of stay, and outcome of the 
patients were noted as well as specific reasons for 
admission. Clinical severity of the disease in terms of 
hemodynamic response was assessed according to the 
SI at the time of ED presentation, which is defined as 
the ratio of the heart rate to systolic blood pressure 
(SI = HR/SBP). SI in normal subjects is 0.50 and a 
higher ratio reflects severity of circulatory shock. We 
adapted a cut-off level of 0.70 in our data set to 
determine the hemodynamic response to the illness 
[15,16]. 
Data was extracted from the patients’ files by the 
research team and double-checked for accuracy 
before analysis. Data was entered and analyzed using 
SPSS version 16 (IBM, Chicago, USA). Frequencies 
and percentages of categorical data were calculated. 
Mean and standard deviation along with median and 
inter-quartile range (IQR) were reported for skewed 
continuous variables. Multiple response analysis was 
used for calculations involving co-morbidities, 
presenting complaints, examination findings, reasons 
for admission in hospital, inpatient treatments, and 
subsequent platelet trends. Keeping the length of stay 
at a cut-off of 48 hours after admission, the 
independent student-t test was applied to assess the 
effect of determinants on length of inpatient hospital 
stay. Level of significance was taken at 95% CI with 
alpha of 0.05. The study was approved by the Ethical 
Review Committee of the university. 
 
Results 
Demographics, presenting symptoms and co-
morbidities of the study participants are given in 
Table 1. A total of 97 patients were included in the 
study. Fever was the most common presentation 
involving 93 (97%) patients. Time duration of fever 
varied with a median span of five days (IQR three 
days) before presentation. A significant number of 
patients had nonspecific complaints along with fever 
including headache, poor oral intake, generalized 
weakness and myalgias, but abdominal complaints 
were observed in almost half of the patients. These 
symptoms included nausea, vomiting, abdominal 
pain, diarrhoea and abdominal distension. About 12% 
of patients had respiratory symptoms including 
shortness of breath and cough; however, one patient 
had adult respiratory distress syndrome (ARDS) at 
the time of presentation. Neurological symptoms 
including confusion, disorientation, and drowsiness 
were present in seven patients and one patient also 
had seizures as a presenting complaint. Decreased 
urinary output was the main complaint in two 
patients along with high-grade fever. 
Mean temperature on arrival was 38 ± 1oC.  
Although mean systolic blood pressure (SBP) was 
normal (114 ± 21 mm of Hg), initial evaluation in the 
ED demonstrated that most of the patients were 
tachycardiac (mean pulse rate 110 ± 22 beats/min). 
Also, 28 (27%) patients had a SBP of less than 100 
mmHg at the time of arrival, requiring aggressive 
fluid replacement. This hemodynamic compromise 
leading to shock is better reflected through the shock 
index (SI). The mean value of SI was 1 (SD = 0.26); 
Median SI was 0.9 (IQR 0.5). Minimal value 
calculated was 0.5 and the maximum was 1.6. 
Hepatomegaly was noted in two patients. Figure 1  
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Characteristics Frequency (Percentage) 
Age Median (IQR) Years 41 (32) 
Gender  
Male 
Female 
 
78 (81) 
19 (19) 
Presenting Symptoms
+
 
Fever with rigors 
Gastrointestinal dysfunction 
Non-specific symptoms 
Respiratory symptoms 
Neurological symptoms 
Renal dysfunction 
Cardiac dysfunction 
 
93 (97) 
54 (67) 
26 (32) 
10 (12) 
  7 (9) 
  2 (2) 
  1 (1) 
Co-Morbidities
+
 
Diabetes mellitus 
Hypertension 
Ischemic heart disease 
Renal disorder 
Infectious disease 
Others* 
 
17 (45) 
16 (42) 
10 (26) 
  7 (18) 
  6 (16) 
15 (39) 
Factors Up to 48 hrs 
Mean (SD†) 
More than 48 
hrs 
Mean (SD) 
p-value 95%CI 
Upper bond 
 
Lower bond 
 
Age 40.5 (17.3) 46.3 (21.8) 0.21 -15.04 3.41 
Days of fever 6.6 (4.1) 8.1 (2.2) 0.10 -.51 5.59 
Systolic BP* 112.0 (20.4) 117.5 (22.0) 0.10 -.51 5.59 
Diastolic BP 67.7 (13.0) 68.9 (12.4) 0.69 -6.80 4.53 
Heart rate 111.3 (22.8) 106.2 (19.7) 0.30 -4.61 14.80 
Temperature 38.2 (1.0) 38.2 (1.1) 0.99 -0.49 0.49 
Oxygen saturation 97.8 (1.5) 97.2 (2.4) 0.22 -.38 1.60 
Hemoglobin 12.6 (1.7) 13.3 (3.9) 0.22 -1.88 .43 
Hematocrit 37.1 (5.1) 37.0 (6.0) 0.89 -2.23 2.56 
Leukocytes  6.5 (3.0) 10.6 (14.6) 0.16 -10.09 1.81 
Platelets 68.6 (52.1) 59.5 (39.0) 0.35 -10.14 28.36 
Serum creatinine 1.1 (0.4) 1.7 (2.7) 0.26 -1.66 .47 
Table 1. Demographics, presenting symptoms, co-morbidities of study participants 
 
*Asthma, benign prostatic hyperplasia, chronic liver disease, vitamin B12 deficiency, 
 seizure disorder, dyslipidemia, factor X deficiency and osteroarthritis 
+Multiple response analysis           IQR interquartile range 
 
Table 2. Comparison of factors affecting participants’ length of stay in hospital 
 
† Standard Deviation *BP Blood Pressure  
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describes the common abnormal physical findings, 
with dehydration, abdominal tenderness, and jaundice 
the most frequently observed signs. 
P. vivax smear was positive in 94 (98%) subjects. 
For the remaining three patients a mix-positive MP-
ICT test along with high-grade fever was taken as a 
proxy indicator, in case the workup for other febrile 
illnesses was negative. Other laboratory workup 
showed mean Hb: 13 ± 3 mg/dl with Haematocrit : 
37 ± 5%, Plt count : 50 x109/L, TLC : 8 ± 9 x109/L 
and SCr : 1 ± 1 mg/dl. Important findings include 88 
(89%) patients who had thrombocytopenia with a 
platelet count of less than 150 x109/L. Half of the 
patients had platelets less than or equal to 50 x 109/L. 
Acute kidney injury marked by decreased urine 
output and high BUN/ creatinine ratio was present in 
45 (46.4%) patients, which improved after fluid 
resuscitation. Abnormal liver function tests (LFTs) 
were reported in 32 (42%) out of 77 patients, in 
whom it was tested. Prolonged prothrombin time 
(PT) and activated partial thromboplastin time 
(aPTT) were noted in 15 (23%) and 12 (19%) 
patients respectively. 
More than 56 patients (58%) were treated with 
chloroquine and 37 (38%) with artemether; another 
17 (18%) received antibiotics at the time of 
presentation, which were discontinued after 
establishment of diagnosis. In one patient anti-
malarial treatment was not documented. While only 
one patient required packed red blood cells 
transfusion, five patients received multiple platelet 
transfusions due to persistently low platelets and 
bleeding complications. The majority of the patients 
(67%) required initial intravenous fluid resuscitation, 
which was continued as in-patient in 43 (44%) 
patients due to dehydration and/or persistent 
vomiting.  
Reasons for admission were mentioned for 84 
patients, out of whom 42 (50%) had low platelets 
with or without bleeding complications; 14 (17%) 
presented with signs and symptoms of septic shock 
requiring continuous monitoring; 4 (5%) had 
electrolyte imbalance including hyponatremia, acute 
renal failure; 2 (2%) had altered mental status at the 
time of presentation; 2 (2%) had concomitant cardiac 
problems; and 1 (1%) had ARDS. The remaining 19 
(23%) were admitted for other reasons including 
dehydration and vomiting/nausea with poor oral 
intake. We also divided the patients according to their 
length of stay in two groups (Table 2). However, the 
analysis failed to demonstrate any statistically 
significant association of the clinical or laboratory 
features such as age, blood pressure, Hb or Plt levels 
with the duration of hospital stay. 
The majority (82; 85%) of the patients were 
admitted in the general ward; 13 (13%) were treated 
in the high dependency or special care units and 2 
(2%) in the intensive care unit. The mean length of 
stay was 2 ± 1 days. The majority, (67; 70%) were 
managed within 48 hours of admission but 29 (30%) 
had to be admitted for more than 48 hours. 
Thirty-eight (39%) patients had co-morbidities 
(Table 1); however, the majority (63%) of the 
patients had less than three chronic illnesses. Among 
the 38 patients with co-morbidities, the reasons for 
admission were similar to those of the rest of the 
patients including thrombocytopenia (n = 3), 
electrolyte imbalance (n = 3) and dehydration (n = 2), 
with the exception of cardiac problems in two 
patients. Only one patient required a platelet 
transfusion in this group and none required 
transfusion of packed RBCs. Twenty-six (68%) 
patients were admitted in the general ward, 10 (26%) 
in the special care ward, and 2 (0.5%) in intensive 
care unit. However, among this subgroup, the 
majority of patients (82%) had SI of more than 0.7. 
Seven cases reported complications during their stay 
in the hospital, including platelet drop, non ST-
elevation myocardial infarction (NSTEMI), 
pneumonia and ARDS. There were no mortalities 
among this subgroup. The number of patients with 
co-morbidities was so small that no statistically 
significant outcome could be measured when 
compared with those who had no co-morbid 
conditions.  
A total of 16 patients had complications during 
their in-hospital stay, such as pneumonia and 
bleeding requiring platelet transfusion. Relapse was 
noted in five patients (5.2%), while ARDS, drug 
induced urticaria and NSTEMI was reported in one 
each.  
 
Discussion 
In this paper we present a cross-sectional study 
describing the characteristics of Vivax malaria 
patients who were managed in a tertiary hospital. 
Despite a small number of subjects over a one-year 
period, we observed that all these patients had signs 
and/or symptoms and laboratory parameters 
warranting in-patient management. 
With respect to presenting complaints, high-
grade fever with generalized body aches and 
gastrointestinal complaints were the commonest 
presentation. The classic description of tertian fever  
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Figure 1. Physical examination findings of study participants+ 
 
Figure 2. Severity index of study participants 
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with high, swinging temperature was found only in a 
minority of patients, while many patients presented 
with non-specific symptoms, abdominal pain, altered 
mental status, vomiting and dehydration which not 
only required laboratory work-up but also 
intravenous fluid resuscitation. Muddaiah and 
Prakash have reported that, among those malaria 
patients who were managed in-hospital, 47% had 
vivax malaria [9]. Also, nausea/vomiting, abdominal 
pain and headaches were observed commonly in 
those who were managed as in-patients [9,10]. Less 
frequently reported but important signs and 
symptoms that were pertinent to the central nervous 
system included drowsiness and seizures, and 
respiratory complications including ARDS and 
respiratory distress. 
Organ dysfunction was noted in a considerable 
proportion of patients who presented with signs of 
systemic sepsis manifested by low blood pressure, 
depressed consciousness, and respiratory and renal 
dysfunction. Andrade and Kaur also reported severe 
P. vivax malaria manifesting as acute renal 
insufficiency and respiratory failure [17-18]. In our 
data set 9% of patients had CNS related symptoms 
including drowsiness and seizures. It is important to 
note that some researchers have identified cerebral 
malaria caused by Plasmodium vivax; however, no 
specific diagnostic tests so far can confirm this 
diagnosis in suspected patients [2,19,20]. 
P. vivax is known to evoke a profound systemic 
inflammatory response as compared to Plasmodium 
falciparum. Some cytokines and vivax-specific 
“malaria toxins” are believed to cause greater organ-
specific inflammation, increased alveolar-capillary 
membrane permeability, capillary leakage, and 
leukocyte aggregation [17,21]. It is responsible for 
respiratory complications such as ARDS and acute 
kidney injury, as described in several case reports 
[14,17,21,22]. A large number of patients with 
hypotension, high shock index, high-grade fever, 
decreased urinary output, and some with respiratory 
complications reflect an intense systemic response 
similar to that of severe sepsis [13,17,18,21]. Higher 
SI ( > 0.7) is related to deteriorating left ventricular 
stroke, as reported by Rady et al. [15,16]. 
Anaemia is a common clinical feature that is 
caused by increased fragility and destruction of 
infected and non-infected RBCs, [9,12,13,17] which 
was not found in our study subjects; the mean 
haemoglobin level was 13 ± 3 mg/dl. However, we 
found a significant number of patients at risk of 
bleeding complications due to low platelet counts. 
Severe thrombocytopenia has been reported by other 
researchers [18,23,24]. Altered thrombostasis, 
thrombocytopenia and microvascular thrombosis 
contribute to bleeding complications and 
microvascular obstruction [13]. Thrombocytopenia at 
the time of admission was one of the major reasons 
for admission in 30% of cases as well as prolonged 
length of stay. Regardless of the platelet levels, only 
5% of the patients developed major bleeding 
complications requiring multiple blood and platelet 
transfusions and most of the patients exhibited a 
rising platelet trend after initiation of antimalarial 
therapy. This finding is supported by other 
investigators in Pakistan. In 2010, Rasheed et al. 
reported such thrombocytopenia [25], and also found 
that despite low platelets, bleeding complications 
were rare and platelets responded well to antimalarial 
therapy. 
Although more than a third of our patients had 
co-morbid conditions, the presenting complaints, 
clinical findings, reasons for admission, and 
complications were similar in both groups. Increased 
severity of SI was noted among those who had no co-
morbidities and also needed in-patient resuscitation. 
The literature supports that the fever and anaemia of 
acute vivax malaria exacerbating hypoxia and/or 
hemodynamic compromise has the potential to 
convert a non-fatal co-morbidity into a fatal one. 
However, in our study, no fatal complications were 
observed. The numbers, however, were so small that 
no statistical results can be obtained. 
Most of the patients were discharged within 48 
hours of admission and the discharge was guided by 
improvement in symptoms coupled with 
hemodynamic stability in the majority of patients 
after confirmation of negative parasitemia and 
improving platelet count. 
The main limitation of our study was its 
retrospective descriptive design. This study was 
neither designed nor powered to predict the risk 
factors associated with severe disease or poor 
prognosis. We included only those patients who were 
treated as in-patients in a single tertiary care centre to 
identify determinants of disease severity warranting 
in-patient care. Also, confirmatory tests such as PCR 
were not routinely performed on these patients. 
This study highlights the fact that the debilitating 
impact of P. vivax malaria, although less than it was 
in former times, remains high. Although the effects 
of severe attacks of P. vivax can be contained through 
aggressive resuscitation, sensitivity toward and 
awareness of this complicated course varies among 
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caregivers. Additional studies are required to find the 
predictors of severe disease, cellular factors or host 
characteristics contributing to certain more frequently 
observed complications. 
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